Recently Diagnosed Early-Stage RRMS: NEDA, ARR, Disability Progression, Serum Neurofilament and Safety: Full Cohort 1-Year Data From the Ocrelizumab▼ Phase IIIb ENSEMBLE Study
Full cohort 1-year efficacy and safety data in an early-stage, treatment-naïve RRMS population receiving treatment with ocrelizumab▼ in the Phase IIIb ENSEMBLE study are reported.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.